Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up
Launched by ANIKA THERAPEUTICS, INC. · Dec 28, 2017
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
Extension Study to Cingal 16-02: Trial Extension to 39 Week Follow Up in the Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Only subjects that were enrolled and met the inclusion criteria for the Cingal 16-02 trial and signed the informed consent are eligible for Cingal 17-02 trial.
- • 2. Subject is able to understand and comply with the requirements of Cingal 17-02 and voluntarily provides consent.
- Exclusion Criteria:
- • Patients will not be rescreened at enrollment to Cingal 17-02 as these patients met the inclusion / exclusion criteria for the Cingal 16-02 clinical trial.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is a global biotechnology company focused on developing and commercializing innovative, patient-centric solutions for orthopedic medicine. With a strong emphasis on regenerative therapies, Anika leverages its expertise in hyaluronic acid-based products to address unmet medical needs, particularly in joint preservation and repair. The company's commitment to advancing science is reflected in its robust pipeline of clinical trials aimed at improving outcomes for patients suffering from musculoskeletal conditions. Anika is dedicated to enhancing patient quality of life through cutting-edge research, strategic partnerships, and a collaborative approach to healthcare innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kiskunfelegyhaza, , Hungary
Gliwice, , Poland
łódź, , Poland
Budapest, , Hungary
Budapest, , Hungary
Budapest, , Hungary
Budapest, , Hungary
Debrecen, , Hungary
Tata, , Hungary
Białystok, , Poland
Bielsko Biała, , Poland
Kraków, , Poland
Toruń, , Poland
Warsaw, , Poland
Warsaw, , Poland
Warsaw, , Poland
świdnik,, , Poland
Gilwice, , Poland
Patients applied
Trial Officials
Laszlo Hangody, MD
Principal Investigator
Uzsoki Hospital, Department of Traumatology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials